In which year will a startup working on morphogenetic approaches to defeating aging reach a $300M+ valuation?
Chance it happens
71%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
Resolves on the year in which a company whose primary work is morphogenetic / bioelectric approaches to reversing or defeating aging first reaches a valuation of at least US$300 million (priced funding round or public listing). Resolution horizon: 2035-12-31. Source: funding announcement / PitchBook / Crunchbase.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a company funding announcement stating that Morphoceuticals closed an $8 million Seed-2 round on February 15, 2023. It is directly relevant because the prediction concerns whether a startup focused on morphogenetic/bioelectric regenerative approaches will eventually reach a $300M+ valuation, and this page establishes an early financing milestone for a plausible candidate company.
This is a PR Newswire funding announcement that Morphoceuticals raised $8 million. It is relevant because Morphoceuticals appears to be a startup in the bioelectric/morphogenetic regeneration space, and early financing is evidence about the trajectory toward a future $300M+ valuation.
This is the company’s own homepage describing Morphoceuticals as a TechBio company focused on the bioelectrome, regeneration, and manipulating bioelectric communication networks in multicellular systems. It is relevant because it is direct evidence that a startup exists in the morphogenetic/bioelectric intervention space that could potentially satisfy the forecast’s company-category requirement.
This is a funding news article about Morphoceuticals, a startup pursuing bioelectric/electroceutical regenerative medicine approaches that appear adjacent to morphogenetic anti-aging work. It is relevant because it provides evidence that such a company exists and is attracting capital, which bears on the likelihood and timing of a future $300M+ valuation, even though the reported round itself is far below the resolution threshold.
This is a 2025 interview/article about Michael Levin's bioelectric and morphogenetic research, directly relevant to the technical area named in the prediction. It also appears to mention Morphoceuticals as a company connected to translating this work, which bears on whether startups in this category could attract major financing and valuation.